It would all hang on 886. There's an unpatented way around 466.
1) There is no particular reason to believe that Teva has worked around 466. (e.g. it is possible that 466 and 886 work in conjunction - either/or/and to prove that your batch is equivalent to gLovenox. I'd have to look a little closer, but in a quick read (on that topic) that looks like a valid read of the pair of patents)
2) Momenta may have chosen not to assert 886 in part to keep some powder dry for the Teva suit (vs airing all of their arguments and allowing Teva time to prepare.).
3) Virtually certain that there is a way to work around each of the patents - and one particular case (Amphastar) wouldn't seem to me to be enough to say it was inherently the easier to bypass.
Market Data 
Markets 
AI
